/C O R R E C T I O N — Health Robotics/

BOZEN, Sud-Tirol, Italy, March 15, 2010 - In the news release, "Health Robotics Reports Record-Breaking Revenues,
EBITDA, Net Profits, and Cash-Flow for its Fiscal Year 2009" issued on 15
Mar 2010 13:20 GMT, by Health Robotics over PR Newswire, we are advised by
a representative of the company that "EUR VAR" has been changed to "$ VAR" in
the third column header of both tables.
Complete, corrected release follows:

Health Robotics today announced FY2009 results, delivering once again
record levels of revenues, profits and cash flow, overcoming a difficult
global economic climate and the short-term consequences of its decision to
terminate non-performing sales and service channels in North America and
Asia-Pacific.

"We are obviously very proud of FY2009 results, which reflect: our
strength and relative immunity versus the global economic crisis; our
continued dominance of the world's IV Automation sector; and our resilience
in quickly overcoming the decision to terminate Devon and its short-term
financial consequences. I'm also satisfied to see that while our direct IV
Robotics competitors fail to even disclose financial results, with tens of
millions of dollars in debt and massive lay-offs as their only available
public information, Health Robotics has no debt, has improved its
cash-on-hand position ten-fold [$1.6M] year-over-year, and for the second
consecutive year distributes in excess of two million US dollars in cash
dividends to its shareholders" stated Werner Rainer, CEO of Health Robotics.

Gross Revenues in FY2009 were $15.1 million, a 31% increase
year-over-year as the company began to record the benefits of its
multi-product offering and continued to profit from its recurring revenue
model and growth in both products and customer base.

Gross Margins including extraordinary items in FY2009 were $8 million, in
line with the prior annual period, as the company recorded an extraordinary
charge of bad debt in connection with the termination of Devon. Not including
the effects of the extraordinary Devon's items, Gross Margins in FY2009 were
$10.7 million, a 32% increase year-over-year. Operating Expenses in FY2009
were $3.4 million, a $1.3 million decrease year-over-year, as the company
benefited from consolidating intellectual property and research and
development activities into a single location, and profiting from the cost
advantages associated with in-sourcing of intellectual property and
manufacturing operations at Trieste as opposed to Loccioni Group's
outsourcing operations at Ancona.

EBIDTA Earnings in FY2009 including extraordinary items were $4.6
million, a 38% increase year-over-year as the company recorded EBITDA
Earnings of 37% of revenues versus 29% in the prior annual period. Not
including the effects of extraordinary items, EBITDA Earnings in FY2009 were
$7.2 million, a 117% increase year-over-year.

Net Profits including extraordinary items were $2.56 million, a 10.1%
increase year-over-year [17% of revenues]. Excluding extraordinary items,
Health Robotics' Net Profits in FY2009 were $4.9 million, a 115% increase
year-over-year [34% of revenues].

"While it was obviously stressful to make drastic changes to our
distribution channels and to take a $2.4 million extraordinary charge to
earnings in FY2009, our decision to irrevocably terminate Devon was
consistent with the importance to Health Robotics of customer satisfaction
and the long-term success of the business over short-term financial gain.
Devon was more preoccupied suing[1] and making legal threats to its own
customers and investors than with staffing service levels to provide adequate
customer support, while concurrently failing to pay Health Robotics during a
six-month period for CytoCare leases and service fees in connection with its
customer installations in America and China, hence our decision to terminate
Devon's contracts for cause. We have now put this unfortunate situation
behind the company, without any lawsuits[2] ever filed against Health
Robotics by anyone anywhere in the world, and starting anew with fiscally
responsible and customer-focused sales and service channels, such as
McKesson, SinoPharm, and HRCI. We will continue to assist as much as legally
possible the innocent victims of Devon's actions and omissions: hospitals who
are now unfortunately embarked in a trail of lawsuits and legal threats to
them by Devon's seeking payments from hospitals for services which Devon
didn't perform and for which Devon did not pay to Health Robotics, as the bad
debt write-offs on our financial statements (attached hereto) denote"
concluded Mr. Rainer.

Additionally, Health Robotics reached many other important non-financial
milestones and success highlights during FY2009: we reached the 50-hospital
customer mark with CytoCare; we installed our second robot for hospital
pharmacies [i.v.STATION]; we successfully launched a new product [i.v. SOFT]
to serve as a back-up to our CytoCare, I,v.STATION and TPNstation robots, and
as the company's entry point into manual sterile compounding; we started the
development of TPNstation; we launched the I.V. Room of the Future
initiative, a joint-development project with selected hospitals to set up 10
centers of I.V. Room excellence around the world (4 in the USA, 1 in Canada,
3 in Europe, and 2 in Asia Pacific); we extended our global reach to 5
continents and more than 20 countries; we were awarded ISO 9001:2008
certification of quality; we translated our products to Czech, Japanese,
French, Spanish, Chinese, Turkish, and German, and more importantly, we
successfully concluded the Safe Chemo project with European Union Government
approval, including peer-reviewed scientific research establishing the fact
that CytoCare is a million times safer that manual compounding.

———————————

[1] Devon Robotics LLC versus the Regents of the University of
Pennsylvania. Court of Common Pleas, Philadelphia.

[2] The only litigation related matter (not a lawsuit) for Health
Robotics was a Devon-filed subpoena simply seeking information from Health
Robotics. This subpoena was quashed by US Federal Court in Las Vegas, even
ordering Devon to pay for Health Robotics' legal expenses. US District Court,
State of Nevada, Case 2:10-cv-00018-RLH-LRL.

              HEALTH ROBOTICS GmbH/S.r.l. (Fiscal Code 02493250217)
            UNAUDITED STATEMENT OF EARNINGS (Thousands of US Dollars)

                              2009       2008     $ VAR      % VAR
                        ---------- ---------- ----------- ----------
    Gross Revenues         $15.061    $11.465     $3.597      31.4%
    Restructuring B/D (a)   $2.630         $0     $2.630      DIV/0
    Revenues Net of B/D    $12.431    $11.465       $967       8.4%

    Cost of Goods Sold      $4.403     $3.372     $1.031      30.6%
    Gross Margin            $8.028     $8.092      ($64)     (0.8%)
                        ---------- ---------- ----------- ----------

    GM%                        53%        71%

    Operating Expenses
    General &
    Administrative          $2.783     $3.727     ($944)    (25.3%)
    Other                     $645     $1.029     ($385)    (37.4%)
                        ---------- ---------- ----------- ----------
    Total Op. Expenses      $3.427     $4.756   ($1.328)    (27.9%)

    EBIDTA                  $4.601     $3.337     $1.264      37.9%
                        ---------- ---------- ----------- ----------

    EBIDTA %                 37.0%      29.1%

    Interest Revenue          $100        $99         $1         1%
    Restructuring
    Charge (b)                $942         $0       $942      DIV/0
    Income Taxes            $1.200     $1.111        $89         8%
    Effective Tax Rate         32%        33%
                        ---------- ---------- ----------- ----------

    Net Earnings            $2.560     $2.325       $235      10.1%
                        ========== ========== =========== ==========

    NET PROFIT %               17%        20%

Note a): Bad Debt Write-Off arising from the termination of Devon as the
distribution channel in North America and China, and Devon's unpaid balance
for CytoCare leases.

Note b): Extraordinary item: one-time legal and employee expenses arising
from Devon's abandonment of customers in North America and China, Devon's
lay-offs of all USA-based employees, and Health Robotics stepping up to the
plate, and responding to both Devon's and customers' requests for Health
Robotics' no-charge CytoCare customer support, during the eight-month
transition of support responsibilities to McKesson Corporation.

              HEALTH ROBOTICS GmbH/S.r.l. (Fiscal Code 02493250217)
                UNAUDITED BALANCE SHEET (Thousands of US Dollars)

                              2009       2008      $ VAR      % VAR
                        ---------- ---------- ----------- ----------

    Assets
    Cash                    $1.583       $154      $1.429     927.4%
    Fixed Assets            $2.607       $395      $2.212     560.0%
    Inventory                 $992       $218        $774     354.7%
    Accounts Receivable     $2.234     $5.289    ($3.055)    (57.8%)
                        ---------- ---------- ----------- ----------

    Total Assets            $7.416     $6.056      $1.360      22.5%

    Liabilities
    Accounts Payable        $1.732     $1.766       ($34)     (1.9%)
    Prov. Income Taxes      $1.025       $682        $342      50.1%
    Accrued Payroll           $141        $84         $57      67.7%
    Short-Term Debt           $552       $874      ($323)    (36.9%)
    Long-Term Debt          $1.669         $0      $1.669      DIV/0
                        ---------- ---------- ----------- ----------

    Total Liabilities       $5.119     $3.407      $1.712      50.3%
                        ---------- ---------- ----------- ----------

    Stockholders' Equity    $2.297     $2.649      ($352)    (13.3%)

    Liabilities & Equity    $7.416     $6.056      $1.360      22.5%
                        ========== ========== =========== ==========

About Health Robotics:

Health Robotics is the undisputed global leading supplier of
life-critical intra-venous medication robots, providing healthcare facilities
in 5 continents with robotics technology and software automation solutions.
Its world-leading solutions CytoCare(TM) [hazardous IVs], i.v.STATION(TM)
[non-hazardous IVs], i.v.SOFT(TM) [workflow engine for manual compounding,
powered by MEDarchiver], and TPNstation(TM) [totally-automated parenteral
nutrition] have and will greatly contribute to ease hospitals' growing
pressures to improve patient safety, increase throughput and contain costs.
Through the effective and efficient production of sterile, accurate,
tamper-evident and ready-to-administer IVs, Health Robotics' solutions help
hospitals eliminate life-threatening drug-exchange errors, decrease other
therapy oversights and sterility risks, work more efficiently, reduce waste
and controlled substances' diversion, and diminish the gap between rising
patient volume/acuity and scarce nursing and pharmacy staff. For more
information, please visit www.health-robotics.com

For additional information, please contact: Health Robotics S.r.l., Gaspar G. DeViedma, Executive V.P., General Counsel, and Member of the Board of Directors, Italy: +39-346-963-4934, USA: +1-609-980-7976, Canada: +1-289470-1456, Malaysia: +60321-848-223, gaspar.deviedma at health-robotics.com